With its highly-skilled workforce, and established R&D and manufacturing capability, the Greek Life Sciences and Pharmaceuticals industry exhibits significant growth potential both in serving its internal market, as well as in expanding its reach beyond national borders. Established players are increasingly pursuing international R&D collaborations for the development of competitive technology-based products. Significant research discoveries have been made by local researchers and there are several start-up and spin-off companies emerging that are in the process of commercialising their innovations.

Greece has to offer a number of advantages to anyone who is active in healthcare and considers doing business in the region: a highly skilled labor force, global excellence in the areas of generics, delivery technologies and drug repositioning, emergining Clinical Trials location with government support and access to EU regulatory authorities.

Essential to this dynamic growth is the Greek R&D infrastructure, which includes internationally renowned Research Institutes, research teams and University Research Groups. The Greek research base includes internationally renowned groups in Research Institutes and Universities. Greece is proud to host several world-class research teams, engaged in leading edge biosciences research and international collaborations with corporate and research players worldwide.


The Hellenic BioCluster (HBio) is the first biosciences cluster in Greece bringing together the innovation leaders of Greece in the sectors of Pharmaceuticals, Biotechnology, Diagnostics, Medical Devices and Specialised Services. Established in 2006 by an initial group of 8 companies and the PRAXI Network, the technology transfer arm of the Foundation for Research & Technology- Hellas (FORTH), the Hellenic BioCluster has grown to date to over 30 innovation-intensive companies with an international outlook.  A frequent interlocutor of the Greek government on matters of policy design in the areas of innovation support and life sciences strategy, HBio aims to boost the development of the Life Sciences industry in Greece, to promote the Greek Life Sciences sector in the international scene and to facilitate business and research collaborations between local and international companies and research groups.

A non-profit organization operating under the auspices of the General Secretariat for Research & Technology, Alexander Flemming Biomedical Research Center focuses on cutting-edge research, aiming to understand molecular mechanisms of complex biological processes in health and disease. The Center is also committed to contribute to innovation in medicine, by developing novel therapeutic and diagnostic methods, focusing on immunity and inflammation, cancer, and neurodegenerative diseases.


Last but not least, the Biomedical Research Foundation of the Academy of Athens (BRFAA) is the most recent addition to the Life Sciences Research establishments in Greece. Established in 2004, it aims to host both basic and clinical research thus providing an ideal setting for the emergence of translational activities. BRFAA is one of the few institutions in Europe with such a character and certainly unique in Greece. The goal of BRFAA is to achieve excellence through the recruitment of high quality investigators carrying out cutting-edge research, and the establishment of state-of-the-art research facilities. BRFAA consists of 4 Research Institutes specialized in different aspects of Biomedical Research.